Antineutrophil cytoplasmic antibody- associated renal vasculitis treated with autologous mesenchymal stromal cells: Evaluation of the contribution of immune-mediated mechanisms

Mayo Clinic Proceedings

Volumn 88, Issue 10, 2013, Pages 1174-1179

  Gregorini, Marilena ^a   Maccario, Rita ^a   Avanzini, Maria Antonietta ^a   Corradetti, Valeria ^a   Moretta, Antonia ^a   Libetta, Carmelo ^a   Esposito, Pasquale ^a   Bosio, Francesca ^a   Dal Canton, Antonio ^a   Rampino, Teresa ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GAMMA INTERFERON; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR;

AGED; ANCA ASSOCIATED RENAL VASCULITIS; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ARTICLE; AUTOLOGOUS MESENCHYMAL STROMA CELL TRANSPLANTATION; CANDIDIASIS; CASE REPORT; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CELL EXPANSION; CELL TRANSPLANTATION; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLOW UP; HEMATURIA; HUMAN; IMMUNE MEDIATED INJURY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY BIOPSY; LEUKOPENIA; MALAISE; MALE; OLIGURIA; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REGULATORY T LYMPHOCYTE; REMISSION; SUPERINFECTION; T LYMPHOCYTE; TREATMENT WITHDRAWAL; URINALYSIS; WEIGHT REDUCTION;

EID: 84888631332     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.06.021     Document Type: Article

References (19)

1. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med. 2010;363(3):285-286.
2. Flint J, Morgan MD, Savage CO. Pathogenesis of ANCAassociated vasculitis. Rheum Dis Clin North Am. 2010;36(3): 463-477.
3. Huugen D, Tervaert JW, Heeringa P. TNF-a bioactivityinhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clin J Am Soc Nephrol. 2006;1(5): 1100-1107.
4. Abdulahad WH, Stegeman CA, van der Geld YM, et al. Functional defect of circulating regulatory CD4p T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 2007;56(6):2080-2091.
5. Morgan MD, Day CJ, Piper KP, et al. Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology. 2010;130(1):64-73.
6. De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012;12(5):574-591.
7. Libetta C, Esposito P, Sepe V, et al. Dialysis treatment and regulatory T cells. Nephrol Dial Transplant. 2010;25(5):1723-1727.
8. Libetta C, Rampino T, Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis. 2001;38(2):286-295.
9. Libetta C, De Nicola L, Rampino T, et al. Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int. 1996;49(2):506-511.
10. Memoli B, Libetta C, De Nicola L, et al. Hemodialysis related interleukin-2 receptor release by peripheral blood mononuclear cells. ASAIO J. 1996;42(1):60-63.
11. Memoli B, Libetta C, Rampino T, et al. Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int. 1992;42(2):320-326.
12. Bernardo ME, Avanzini MA, Perotti C, et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol. 2007;211(1): 121-130.
13. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007; 67(19):9142-9149.
14. Bernardo ME, Avanzini MA, Ciccocioppo R, et al. Phenotypical/ functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy. 2009;11(7):825-836.
15. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011;60(6):788-798.
16. Moretta A, Tambussi G, Bottino C, et al. A novel surface antigen expressed by a subset of human CD3- CD16p natural killer cells: role in cell activation and regulation of cytolytic function. J Exp Med. 1990;171(3):695-714.
17. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials [published online ahead of print October 25, 2012]. PLoS One. 2012;7(10):e47559.
18. Kelesidis T, Daikos G, Boumpas D, et al. Does rituximab increase the incidence of infectious complications? a narrative review. Int J Infect Dis. 2011;15(1):e2-e16.
19. Wall N, Harper L. Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol. 2012; 8(9):523-532.